{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2007"],"condition":["Previously untreated Patients with Colorectal Cancer and Advanced Liver Metastases.","Colorectal cancer metastatic"],"disease":["Previously Untreated Patients With Colorectal Cancer And Advanced Liver Metastases.","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2522081"],"location":["Italy"],"study_start_month":["8"],"keyword":["Oxaliplatin","Capecitabine","Vectibix"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Phase II Clinical Trial of Panitumumab in Combination with Infusional Oxaliplatin and Oral Capecitabine (XELOX) Chemotherapy as 1st line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases","description":"Primary objectives: To assess the objective response rate (ORR) over the entire treatment period when panitumumab is administered in combination with XELOX chemotherapy as 1st-line therapy in patients with previously untreated colorectal cancer and advanced liver metastases.\nPrimary endpoints: Objective Response Rate (ORR) over the entire treatment period (the proportion of subject’s in the ITT analysis set with a confirmed complete or partial response). Subject’s who do not respond will be considered a non-responder in the analysis.","dates":{"creation":"2007-08-15"},"accession":"2522081","cross_references":{"EU Clinical Trials Register":["2007-002007-41"]}}